OAC2
目录号 : GC17327
An Oct4-activating compound
Cas No.:6019-39-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | The Oct4-luc or Nanog-luc cells are treated with compound OAC1 or its structural analogs OAC2, OAC3 at 1 μM concentration or at indicated concentrations. Other compounds used include 2 μM BIO, 2 μM BIX, 2 μM 5'-azacytidine, 25 μg/mL Vitamin C, 10 nM Am580, 5 μM tranylcypromine, and 0.5 mM valporic acid. Luciferase reporter assays are performed 24 h after compound treatment or at indicated time points. For Topflash reporter assays, 0.2 μg β-catenin–responsive Topflash reporter gene plasmid is introduced into CV1 cells using trasfection. Compounds are added 6 h after transfection. Luciferase activity is measured 48 h after compound treatment using the Glo Luciferase Assay System[2]. |
References: [1]. Okuyama T, et al. Structural and mechanistic insights into nuclear transport and delivery of the critical pluripotency factor Oct4 to DNA. J Biomol Struct Dyn. 2017 Feb 6:1-50 | |
OAC2 is identified as an activator of octamer-binding transcription factor 4.
Octamer-binding transcription factor 4 (Oct4) has been found to be a key regulator of embryonic stem cell (ESC) pluripotency and cirtical to the reprogramming process.
In vitro: OAC2 was found to be able to activate both Oct4 and Nanog reporters to a similar extent as OAC1, which was the OAC analog showing greatest activating effects on both Oct4 and Nanog promoter-driven luciferase reporter genes. Moreover, in order to examine the developmental potential of 4F+OAC1- and 4F+OAC2-iPSCs, the authors differentiated such cells in vitro by using a standard embryoid body differentiation method. The immunostaining results showed that both the 4F+ OAC1-iPSCs and 4F+OAC2-iPSCs were able to effectively differentiate into characteristic smooth muscle actin (SMA)+ mesodermal cells, FoxA2+ endoderm cells, and Tuj1+ ectoderm cells as well [1].
In vivo: In animal to test the in vivo pluripotency of the 4F+ OAC2-induced iPSCs, the 4F+OAC2-iPSCs were transplanted the into immunodeficient Nude mice. Four to 6 weeks after transplantation, the 4F+OAC2-iPSCs could generate typical teratomas containing derivative of all three germ layers effectively, such as blood of mesoderm, intestinal epithelia of endoderm, as well as epidermis of ectoderm [1].
Clinical trial: Up to now, OAC2 is still in the preclinical development stage.
Reference:
[1] Li W,Tian E,Chen ZX,Sun G,Ye P,Yang S,Lu D,Xie J,Ho TV,Tsark WM,Wang C,Horne DA,Riggs AD,Yip ML,Shi Y. Identification of Oct4-activating compounds that enhance reprogramming efficiency. Proc Natl Acad Sci U S A.2012 Dec 18;109(51):20853-8.
| Cas No. | 6019-39-2 | SDF | |
| 化学名 | N-(1H-indol-5-yl)benzamide | ||
| Canonical SMILES | O=C(NC1=CC=C2C(C=CN2)=C1)C3=CC=CC=C3 | ||
| 分子式 | C15H12N2O | 分子量 | 236.27 |
| 溶解度 | ≥ 23.6mg/mL in DMSO, ≥ 24.4 mg/mL in EtOH with ultrasonic | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.2324 mL | 21.1622 mL | 42.3245 mL |
| 5 mM | 0.8465 mL | 4.2324 mL | 8.4649 mL |
| 10 mM | 0.4232 mL | 2.1162 mL | 4.2324 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。